Vasoactive Intestinal Peptide: A Neuropeptide That Directly Controls Immune Cells and Inflammation
VIP is a neuropeptide produced by both neurons and immune cells that acts as a major immunoregulatory molecule, suppressing inflammation and showing therapeutic potential for autoimmune diseases.
Quick Facts
What This Study Found
VIP is widely distributed in the central and peripheral nervous system and is also synthesized by immune cells, which express VIP receptors — creating an autocrine/paracrine immunoregulatory loop. VIP contributes to immune privilege in organs like the CNS (central nervous system) by maintaining immune deviation, and controls acute inflammation in peripheral immune organs.
The review summarizes VIP's broad immunomodulatory effects: it generally suppresses pro-inflammatory responses, shifts T cell differentiation toward regulatory phenotypes, and modulates cytokine production. Both endogenous VIP (naturally produced) and exogenous VIP (administered therapeutically) show potential in inflammatory and autoimmune disorders.
Key Numbers
How They Did This
This is a comprehensive review article synthesizing current literature on VIP biology in the immune system. It covers VIP production by neurons and immune cells, VIP receptor expression and signaling, VIP effects on various immune cell types, and VIP's role in animal models and clinical observations of inflammatory and autoimmune diseases.
Why This Research Matters
The nervous system and immune system are deeply interconnected, but the mechanisms of this communication are still being elucidated. VIP represents one of the clearest examples of a neuropeptide directly controlling immune function. Understanding this could lead to new treatments for autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease — conditions where the immune system attacks the body's own tissues.
The Bigger Picture
VIP exemplifies the emerging understanding that the nervous and immune systems are not separate but deeply integrated. The concept of 'neuroimmunology' — where neuropeptides modulate immune responses — has implications far beyond VIP, touching on stress-related immune dysfunction, neuroinflammation in neurodegenerative diseases, and the gut-brain axis. VIP's role in immune privilege also has implications for understanding why certain organs (brain, eyes, testes) tolerate foreign antigens differently.
What This Study Doesn't Tell Us
As a review article, this does not present new experimental data. Much of the evidence comes from animal models, and clinical translation of VIP-based therapies has been limited by VIP's short half-life and multiple biological effects. The review focuses on VIP's immunosuppressive properties, but VIP can have context-dependent effects that complicate therapeutic application. Specificity of VIP receptor targeting for therapeutic benefit without side effects remains a challenge.
Questions This Raises
- ?Can VIP analogs with improved stability be developed for clinical treatment of autoimmune diseases?
- ?How does VIP balance its immunosuppressive role with the need for immune defense against infections?
- ?Could VIP receptor agonists be used to restore immune privilege in organ transplantation?
Trust & Context
- Key Stat:
- Dual-source immunomodulator VIP is produced by both neurons and immune cells themselves, creating a bidirectional communication system between the nervous and immune systems that maintains immune tolerance and controls inflammation.
- Evidence Grade:
- This is a comprehensive review published in Acta Physiologica, synthesizing preclinical and limited clinical evidence. While it provides an excellent overview of VIP immunobiology, the therapeutic applications discussed remain largely preclinical.
- Study Age:
- Published in 2015, this review captures the state of VIP immunobiology knowledge at that time. VIP-based therapeutic approaches have continued to be explored, particularly with modified analogs that have improved pharmacokinetic properties.
- Original Title:
- The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.
- Published In:
- Acta physiologica (Oxford, England), 213(2), 442-52 (2015)
- Authors:
- Ganea, D, Hooper, K M, Kong, W
- Database ID:
- RPEP-02636
Evidence Hierarchy
Frequently Asked Questions
What is VIP and how does it affect the immune system?
Vasoactive intestinal peptide (VIP) is a signaling molecule produced by nerve cells and immune cells. It generally suppresses inflammation, shifts immune responses toward tolerance, and helps maintain immune privilege in organs like the brain. These properties make it a potential therapeutic target for autoimmune diseases.
Could VIP-based treatments help autoimmune diseases?
VIP shows promise in animal models of autoimmune diseases by dampening the overactive immune response that causes tissue damage. The main challenge is that natural VIP breaks down very quickly in the body. Researchers are developing modified versions with longer activity to make clinical treatment feasible.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02636APA
Ganea, D; Hooper, K M; Kong, W. (2015). The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.. Acta physiologica (Oxford, England), 213(2), 442-52. https://doi.org/10.1111/apha.12427
MLA
Ganea, D, et al. "The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.." Acta physiologica (Oxford, 2015. https://doi.org/10.1111/apha.12427
RethinkPeptides
RethinkPeptides Research Database. "The neuropeptide vasoactive intestinal peptide: direct effec..." RPEP-02636. Retrieved from https://rethinkpeptides.com/research/ganea-2015-the-neuropeptide-vasoactive-intestinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.